Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study

V. Pistoia, A. Buoncompagni, R. Scribanis, L. Fasce, G. Alpigiani, G. Cordone, M. Ferrarini, C. Borrone, F. Cottafava

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In this study we have investigated the efficacy and safety of cyclopsorin A (CyA) in a group of pediatric patients with juvenile chronic arthritis (JCA, 9 cases) and polymyositis-dermatomyositis (PM-DM, 3 cases). Of the 9 JCA patients, 7 had the systemic and 2 the polyarticular form of the disease. All of the patients received CyA after the failure of corticosteroids and/or cytotoxic drugs. CyA was administered for 9 to 48 months at a mean dose of 5 mg/kg/day. Ten patients received corticosteroids with CyA. The results of CyA treatment were satisfactory overall, both in the PM-DM patients and in the JCA patients, as assessed by clinical and laboratory evaluation. CyA-related side effects included alopecia, hypertension, hypertrichosis, tremors, and hirsutism. One JCA patient developed polyserositis with hypoproteinemia of unknown origin while receiving CyA. CyA blood levels did not correlate with clinical efficacy and/or side effects. This study suggests that CyA represents a promising agent for the treatment of JCA and childhood PM-DM.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalClinical and Experimental Rheumatology
Volume11
Issue number2
Publication statusPublished - 1993

Fingerprint

Dermatomyositis
Juvenile Arthritis
Cyclosporine
Therapeutics
Adrenal Cortex Hormones
Hypertrichosis
Hypoproteinemia
Hirsutism
Alopecia
Tremor
Pediatrics
Hypertension
Safety
Pharmaceutical Preparations

Keywords

  • cyclosporin A
  • juvenile chronic arthritis

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. / Pistoia, V.; Buoncompagni, A.; Scribanis, R.; Fasce, L.; Alpigiani, G.; Cordone, G.; Ferrarini, M.; Borrone, C.; Cottafava, F.

In: Clinical and Experimental Rheumatology, Vol. 11, No. 2, 1993, p. 203-208.

Research output: Contribution to journalArticle

Pistoia, V, Buoncompagni, A, Scribanis, R, Fasce, L, Alpigiani, G, Cordone, G, Ferrarini, M, Borrone, C & Cottafava, F 1993, 'Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study', Clinical and Experimental Rheumatology, vol. 11, no. 2, pp. 203-208.
Pistoia, V. ; Buoncompagni, A. ; Scribanis, R. ; Fasce, L. ; Alpigiani, G. ; Cordone, G. ; Ferrarini, M. ; Borrone, C. ; Cottafava, F. / Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study. In: Clinical and Experimental Rheumatology. 1993 ; Vol. 11, No. 2. pp. 203-208.
@article{43d35358f89949dab2f3845e762757cd,
title = "Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study",
abstract = "In this study we have investigated the efficacy and safety of cyclopsorin A (CyA) in a group of pediatric patients with juvenile chronic arthritis (JCA, 9 cases) and polymyositis-dermatomyositis (PM-DM, 3 cases). Of the 9 JCA patients, 7 had the systemic and 2 the polyarticular form of the disease. All of the patients received CyA after the failure of corticosteroids and/or cytotoxic drugs. CyA was administered for 9 to 48 months at a mean dose of 5 mg/kg/day. Ten patients received corticosteroids with CyA. The results of CyA treatment were satisfactory overall, both in the PM-DM patients and in the JCA patients, as assessed by clinical and laboratory evaluation. CyA-related side effects included alopecia, hypertension, hypertrichosis, tremors, and hirsutism. One JCA patient developed polyserositis with hypoproteinemia of unknown origin while receiving CyA. CyA blood levels did not correlate with clinical efficacy and/or side effects. This study suggests that CyA represents a promising agent for the treatment of JCA and childhood PM-DM.",
keywords = "cyclosporin A, juvenile chronic arthritis",
author = "V. Pistoia and A. Buoncompagni and R. Scribanis and L. Fasce and G. Alpigiani and G. Cordone and M. Ferrarini and C. Borrone and F. Cottafava",
year = "1993",
language = "English",
volume = "11",
pages = "203--208",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "2",

}

TY - JOUR

T1 - Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study

AU - Pistoia, V.

AU - Buoncompagni, A.

AU - Scribanis, R.

AU - Fasce, L.

AU - Alpigiani, G.

AU - Cordone, G.

AU - Ferrarini, M.

AU - Borrone, C.

AU - Cottafava, F.

PY - 1993

Y1 - 1993

N2 - In this study we have investigated the efficacy and safety of cyclopsorin A (CyA) in a group of pediatric patients with juvenile chronic arthritis (JCA, 9 cases) and polymyositis-dermatomyositis (PM-DM, 3 cases). Of the 9 JCA patients, 7 had the systemic and 2 the polyarticular form of the disease. All of the patients received CyA after the failure of corticosteroids and/or cytotoxic drugs. CyA was administered for 9 to 48 months at a mean dose of 5 mg/kg/day. Ten patients received corticosteroids with CyA. The results of CyA treatment were satisfactory overall, both in the PM-DM patients and in the JCA patients, as assessed by clinical and laboratory evaluation. CyA-related side effects included alopecia, hypertension, hypertrichosis, tremors, and hirsutism. One JCA patient developed polyserositis with hypoproteinemia of unknown origin while receiving CyA. CyA blood levels did not correlate with clinical efficacy and/or side effects. This study suggests that CyA represents a promising agent for the treatment of JCA and childhood PM-DM.

AB - In this study we have investigated the efficacy and safety of cyclopsorin A (CyA) in a group of pediatric patients with juvenile chronic arthritis (JCA, 9 cases) and polymyositis-dermatomyositis (PM-DM, 3 cases). Of the 9 JCA patients, 7 had the systemic and 2 the polyarticular form of the disease. All of the patients received CyA after the failure of corticosteroids and/or cytotoxic drugs. CyA was administered for 9 to 48 months at a mean dose of 5 mg/kg/day. Ten patients received corticosteroids with CyA. The results of CyA treatment were satisfactory overall, both in the PM-DM patients and in the JCA patients, as assessed by clinical and laboratory evaluation. CyA-related side effects included alopecia, hypertension, hypertrichosis, tremors, and hirsutism. One JCA patient developed polyserositis with hypoproteinemia of unknown origin while receiving CyA. CyA blood levels did not correlate with clinical efficacy and/or side effects. This study suggests that CyA represents a promising agent for the treatment of JCA and childhood PM-DM.

KW - cyclosporin A

KW - juvenile chronic arthritis

UR - http://www.scopus.com/inward/record.url?scp=0027322531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027322531&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 203

EP - 208

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 2

ER -